德国将在未来几个月借入比原计划多大约五分之一的资金以应对支出激增。同时，一项总额达460亿欧 元(530亿美元)的减税协议也凸显了德国发债需求的上升趋势。提高第三季度发债规模以及减税措施都 是总理弗里德里希.默茨领导的执政联盟为振兴疲软的德国经济、加强军队建设所采取的部分举措。德 国内阁还批准了今年的预算案和政府的中期财政规划，后者包括到2029年底净新增借款约5000亿欧元。 根据周二公布的最新计划，负责管理联邦债务的德国财政署将在7月至9月期间筹集1185亿欧元资金，比 去年12月最初公布的计划多出190亿欧元。德国长期国债下跌，30年期国债收益率上涨了多达10个基点 至3.06%，为5月末以来的最高水平。(新浪财经) ...

｜2025年6月25日星期三｜ NO.1 拨康视云-B在港交所启动招股 6月24日，眼科生物科技公司拨康视云-B（HK02592）在港交所启动招股，预计7月3日在港交所挂牌上市。该公司拟全球发售约6058万股股 份，其中，90%为国际发售，10%为公开发售，无超额配股权。每股发售价10.10港元，每手500股。该公司专注于内部发现、开发及商业化同 类首创及同类最佳眼科疗法，已建立一个由八种候选药物组成的广泛而创新的管线。 点评：这表明了公司积极扩张的意图，无超额配股权的安排可能显示出公司对自身价值的信心。投资者应关注其后续市场表现和药物研发进 展。 NO.2 斯坦德机器人递表港交所 6月23日，深圳承泰科技股份有限公司（以下简称"承泰科技"）向港交所递交招股书。该公司是毫米波雷达的供应商，一直从事毫米波雷达产 品的设计、研发、制造和商业化。2022年至2024年，承泰科技营收分别为0.58亿元、1.57亿元和3.48亿元，净亏损分别为0.79亿元、0.97亿元和 0.22亿元。 点评：随着技术的进步和市场需求的增长，承泰科技有望在未来实现盈利。投资者应密切关注其上市进展和财务状况，特别是营收增长和亏损 缩小的 ...

智通财经6月24日电，中概股走强，纳斯达克中国金龙指数涨近3%，小马智行涨逾13%，新东方涨逾 12.7%，禾赛涨12.4%，金山云涨6.7%。 ...

从中华交易服务香港生物科技指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中华交易服务香港生物科技指数持仓样本的行业来看，生物药品占比56.98%、制药与生物科技服务 占比24.70%、化学药占比16.03%、医疗器械占比2.29%。 金融界6月24日消息，上证指数低开高走，中华交易服务香港生物科技指数 (中华香港生物科技， CESHKB)上涨3.66%，报7559.76点，成交额121.13亿元。 数据统计显示，中华交易服务香港生物科技指数近一个月上涨15.96%，近三个月上涨28.51%，年至今 上涨62.76%。 据了解，"中华交易服务香港生物科技指数由中华证券交易服务有限公司(中华交易服务)委托中证指数 有限公司(中证指数)进行编制，指数编制方案由中华交易服务以及中证指数共同确定。中华交易服务香 港生物科技指数(中华香港生物科技)为证券价格指数，旨在反映于香港上市的生物科技公司的整体表 现"该指数以2014年12月12日为基日，以2000.0点为基点。 从指数持仓来看，中华交易服务香港生物科技指数十大权重分别为：康方生物（10.79%）、信达生物 （10.03%）、百济神州（9.56%） ...

Core Insights - Meituan has made significant strategic adjustments to its retail business, pausing its community group buying service "Meituan Youxuan" in many regions across China, except for a few areas like Guangdong and Zhejiang, while focusing on expanding its instant retail services centered around "Meituan Flash Purchase" and "Little Elephant Supermarket" [3][4] Group 1: Community Group Buying Landscape - The community group buying sector began in 2016 and saw rapid growth with major players like Didi, Meituan, and Pinduoduo entering the market around 2020 [3] - By 2021, many community group buying platforms faced significant challenges, with several shutting down or pivoting to other business models, such as Tongcheng Life filing for bankruptcy and Orange Heart Selection closing down [3][4] - As of March 2023, Alibaba's community group buying service Taobao Grocery also ceased its nationwide next-day pickup service, leaving Pinduoduo's "Duoduo Grocery" as one of the few remaining players in the market [3][4] Group 2: Financial Challenges and Market Dynamics - The community group buying sector experienced a "subsidy war" starting in 2020, with Meituan investing over 6 billion yuan in subsidies within a few months to cover over 2,000 cities and counties [4] - By 2021, the industry began to cool down as platforms reduced excessive subsidies, leading to a significant drop in customer orders due to diminished price advantages [4] - Meituan reported a staggering loss of 38.4 billion yuan in its new business segment in 2021, with the "Youxuan" service being a major contributor to these losses [4][5] Group 3: Transition to Instant Retail - Despite challenges, the community group buying market still holds substantial potential, with projections indicating sales could exceed 3.5 trillion yuan by 2025 [6] - Meituan plans to leverage its existing supply chain and distribution network to explore new community retail models, including a "next-day delivery + pickup" approach [6] - Pinduoduo is testing self-built warehouses in major cities and plans to launch instant delivery services by August 2024, indicating a shift towards more efficient logistics and service offerings [6]

有消息称，泡泡玛特或许要跨界进军家电行业。据媒体报道，近日，有网友发帖称泡泡玛特进军家电行 业，该网友称某招聘平台上泡泡玛特HR正在招聘家电行业相关人才。对此，新浪科技向泡泡玛特官方 求证，截至发稿对方暂无回应。(新浪科技) ...

Core Insights - The 2025 Summer Davos Forum will be held in Tianjin from June 24-26, focusing on the theme of "Entrepreneurial Spirit in the New Era" [1] Group 1: AI in Healthcare - AI technology can significantly enhance the quality of medical diagnosis and treatment by integrating years of patient medical history into a visual timeline, allowing doctors to better understand patient conditions [3] - The AI decision support system can provide multiple treatment suggestions for complex cases, aiding doctors in making more accurate clinical decisions [3] - Clinical trial costs have been reduced by 30%-40% due to the integration of AI and data platforms, which can automate many previously manual processes [3] Group 2: Industry Challenges and Opportunities - The healthcare industry is challenging to navigate, with recent market and policy changes prompting the company to adopt a cautious approach to commercialization [4] - The recent activity in the secondary market for innovative drugs reflects a valuation correction, recognizing China's potential as a research-driven market [4] - The Chinese biopharmaceutical ecosystem is expected to grow, with more companies pursuing international collaborations and contributing to global healthcare [4] Group 3: Future Outlook - Future healthcare scenarios envision the integration of historical medical data with wearable devices, providing a comprehensive understanding of individual health and 24/7 personalized health advice through AI [5] - AI is expected to significantly lower new drug development costs, helping more drugs avoid the "orphan drug" dilemma [5] - Insurance coverage is anticipated to expand, with initiatives like the company's "Hui Min Bao" providing coverage for a wide range of patients, including those with pre-existing conditions [5]

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with type 2 diabetes ...

Group 1 - Wuhan Dazhong Dental Medical Co., Ltd. has passed the listing hearing on the Hong Kong Stock Exchange on June 24 [1] - The exclusive sponsor for the listing is Haitong International [1]

智通财经APP讯，HOME CONTROL(01747)及要约人Meta-Wisdom Tech Limited联合公布，于2025年6月 24日，要约人(作为买方)与卖方(作为卖方)订立买卖协议，要约人已有条件同意购买而卖方已有条件同 意出售销售股份，即3.75亿股股份，占本联合公告日期已发行股份总数约74.02%。 销售股份的总代价为2.3亿港元，相当于每股销售股份约0.6133港元，惟可作出以下潜在代价调整：倘于 交割后卖方收到本公司支付的2024年末期股息，则卖方须向要约人支付相等于所收到2024年末期股息的 款项。交易代价乃由要约人与卖方公平磋商并经考虑(其中包括)股份的过往市价及交易流通量以及本公 司的上市地位而达致。 交割已于2025年6月24日落实。 紧接交割前，要约人及要约人一致行动人士并无持有、拥有、控制或指示本公司的任何股份或其他相关 证券(定义见收购守则规则22註释4)。紧随交割后及于本联合公告日期，要约人拥有3.75亿股股份(占已 发行股份总数约74.02%)。因此，要约人须根据收购守则规则26.1就所有已发行股份(要约人已拥有或同 意收购者除外)作出强制性无条件全面要约。 每股要约 ...